Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) saw a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 10,235,812 shares, a decrease of 11.1% from the August 31st total of 11,514,444 shares. Approximately 8.3% of the company’s stock are short sold. Based on an average daily volume of 948,653 shares, the short-interest ratio is currently 10.8 days.

In other news, Chairman Stanley T. Crooke sold 16,500 shares of the company’s stock in a transaction on Monday, July 17th. The shares were sold at an average price of $52.45, for a total value of $865,425.00. Following the transaction, the chairman now directly owns 53,014 shares of the company’s stock, valued at $2,780,584.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Ionis Pharmaceuticals Inc purchased 3,125,000 shares of the company’s stock in a transaction dated Wednesday, July 19th. The stock was bought at an average cost of $8.00 per share, for a total transaction of $25,000,000.00. Following the completion of the purchase, the insider now directly owns 28,884,540 shares of the company’s stock, valued at approximately $231,076,320. The disclosure for this purchase can be found here. Insiders sold a total of 38,500 shares of company stock worth $2,122,175 in the last quarter. 1.86% of the stock is owned by corporate insiders.

Several large investors have recently bought and sold shares of the business. Intl Fcstone Inc. bought a new stake in shares of Ionis Pharmaceuticals during the 2nd quarter worth approximately $598,000. WFG Advisors LP boosted its holdings in shares of Ionis Pharmaceuticals by 77.2% in the 2nd quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock valued at $193,000 after buying an additional 1,655 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Ionis Pharmaceuticals in the 2nd quarter valued at approximately $381,000. Verition Fund Management LLC acquired a new stake in shares of Ionis Pharmaceuticals in the 2nd quarter valued at approximately $742,000. Finally, Bank of Nova Scotia acquired a new stake in shares of Ionis Pharmaceuticals in the 2nd quarter valued at approximately $1,526,000. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Ionis Pharmaceuticals (NASDAQ IONS) opened at 50.70 on Monday. The company has a market cap of $6.30 billion, a P/E ratio of 243.75 and a beta of 3.13. The company has a 50-day moving average of $51.73 and a 200 day moving average of $48.15. Ionis Pharmaceuticals has a one year low of $24.58 and a one year high of $60.01.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.03). Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. The company had revenue of $104.15 million for the quarter, compared to the consensus estimate of $93.29 million. During the same quarter in the previous year, the company posted ($0.47) EPS. The business’s revenue was up 170.7% on a year-over-year basis. Equities research analysts predict that Ionis Pharmaceuticals will post ($0.17) EPS for the current year.

Several research analysts have weighed in on IONS shares. TheStreet raised Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Wednesday, July 5th. Stifel Nicolaus reiterated a “hold” rating and set a $42.00 price target on shares of Ionis Pharmaceuticals in a report on Monday, July 10th. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a report on Wednesday, July 12th. BMO Capital Markets reissued an “outperform” rating and issued a $62.00 price target (up previously from $59.00) on shares of Ionis Pharmaceuticals in a research note on Wednesday, July 12th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a research note on Wednesday, July 26th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. Ionis Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $49.11.

TRADEMARK VIOLATION NOTICE: “Ionis Pharmaceuticals, Inc. (IONS) Short Interest Update” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/ionis-pharmaceuticals-inc-ions-short-interest-update/1601932.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.